AbbVie Inc.
AbbVie Inc. (4AB.DU) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for AbbVie Inc. (4AB.DU), featuring income statements, balance sheets, and cash flow data.
AbbVie Inc. (4AB.DU) Income Statement & Financial Overview
Review AbbVie Inc. 4AB.DU income statement with detailed quarterly and annual figures.
| Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| Revenue | $15.42B | $13.34B | $15.10B | $14.46B |
| Cost of Revenue | $4.002B | $4.002B | $4.40B | $4.21B |
| Gross Profit | -$9.34B | $9.34B | $10.71B | $10.25B |
| Gross Profit Ratio | -$0.61 | $0.70 | $0.71 | $0.71 |
| R&D Expenses | $2.13B | $2.07B | $6.77B | $2.13B |
| SG&A Expenses | $3.25B | $3.29B | $2.88B | $4.21B |
| Operating Expenses | $6.53B | $5.61B | $12.20B | $6.42B |
| Total Costs & Expenses | $10.53B | $9.61B | $16.59B | $10.63B |
| Interest Income | -$73.00M | $73.00M | $92.00M | $129.00M |
| Interest Expense | $605.00M | $700.00M | $702.00M | $720.00M |
| Depreciation & Amortization | -$2.04B | $2.04B | $2.10B | $2.08B |
| EBITDA | $117.00M | $4.40B | $535.00M | $4.88B |
| EBITDA Ratio | $0.008 | $0.33 | $0.04 | $0.34 |
| Operating Income | -$3.76B | $3.73B | -$1.49B | $3.83B |
| Operating Income Ratio | -$0.24 | $0.28 | -$0.10 | $0.26 |
| Other Income/Expenses (Net) | $0.00 | -$2.07B | -$779.00M | -$1.75B |
| Income Before Tax | $1.55B | $1.66B | -$2.27B | $2.08B |
| Income Before Tax Ratio | $0.10 | $0.12 | -$0.15 | $0.14 |
| Income Tax Expense | $613.00M | $372.00M | -$2.25B | $520.00M |
| Net Income | $938.00M | $1.29B | -$22.00M | $1.56B |
| Net Income Ratio | $0.06 | $0.10 | -$0.001 | $0.11 |
| EPS | $4.71 | $0.72 | -$0.02 | $0.88 |
| Diluted EPS | $4.71 | $0.72 | -$0.02 | $0.88 |
| Weighted Avg Shares Outstanding | $1.77B | $1.77B | $1.77B | $1.77B |
| Weighted Avg Shares Outstanding (Diluted) | $1.77B | $1.77B | $1.77B | $1.77B |
The company's financials show resilient growth, with revenue advancing from $14.46B in Q3 2024 to $15.42B in Q2 2025. Gross profit remained healthy with margins at -61% in Q2 2025 compared to 71% in Q3 2024. Operating income hit -$3.76B last quarter, sustaining a consistent -24% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $117.00M. Net income dropped to $938.00M, while earnings per share reached $4.71. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan